AtriCure, Inc. (ATRC) Stock Analysis
Recovery setup
Healthcare · Medical Instruments & Supplies
Hold if already holding. Not a fresh buy at $28.80, but acceptable to hold if already in. Reasons: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2); Below 200-MA, MA slope -1.5%/30d (confirmed downtrend).
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and... Read more
Hold if already holding. Not a fresh buy at $28.80, but acceptable to hold if already in. Reasons: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2); Below 200-MA, MA slope -1.5%/30d (confirmed downtrend). Chart setup: Death cross but MACD improving, RSI 59. Mixed signals. Hold existing position. Score 5.6/10, moderate confidence.
Passes 8/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 70d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent Developments — AtriCure, Inc.
Latest news
- AtriCure stock hits 52-week low at $27.04 By Investing.com - Investing.com Australia — Investing.com Australia negative
- AtriCure (NASDAQ:ATRC) Reaches New 52-Week Low - What's Next? - MarketBeat — MarketBeat negative
- AtriCure stock hits 52-week low at $27.04 - Investing.com — Investing.com negative
- AtriCure, Inc. (NASDAQ:ATRC) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat — MarketBeat positive
- Here's What Key Metrics Tell Us About AtriCure (ATRC) Q1 Earnings - Yahoo Finance — Yahoo Finance positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $28.80, but acceptable to hold if already in. Reasons: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2); Below 200-MA, MA slope -1.5%/30d (confirmed downtrend). Chart setup: Death cross but MACD improving, RSI 59. Mixed signals. Hold existing position. Target $40.89 (+42.0%), stop $26.78 (−7.5%), A.R:R 3.7:1. Score 5.6/10, moderate confidence.
Take-profit target: $40.89 (+42.0% upside). Target $40.89 (+42.0%), stop $26.78 (−7.5%), A.R:R 3.7:1. Stop-loss: $26.78.
V7 low-quality RISK_OFF penalty: -0.5 (Q=4.2); Below 200-MA, MA slope -1.5%/30d (confirmed downtrend).
AtriCure, Inc. trades at a P/E of N/A (forward 81.7). TrendMatrix value score: 7.4/10. Verdict: Hold.
16 analysts cover ATRC with a consensus score of 4.1/5. Average price target: $47.
What does AtriCure, Inc. do?AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue,...
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.